ScandiDos, Varian sign distributor agreement for Delta4PT pre-treatment verification system

NewsGuard 100/100 Score

Varian Medical Systems and ScandiDos AB hereby announce that the companies have signed a non-exclusive distributor agreement.  The agreement covers the ScandiDos Delta4PT pre-treatment verification system, for use with Varian's RapidArc® radiotherapy technology, the TrueBeam™ system, and Varian's technology for IMRT. The agreement allows Varian and its affiliates world-wide to offer Delta4PT to their customers, providing additional solutions for fast and accurate verification of complex radiation therapy technologies.

ScandiDos Delta4PT QA system is a quality assurance tool used to test radiotherapy treatment plans to help insure that they will result in the desired dose distribution before actual treatments commence.  It allows the users to quickly verify and approve the delivery of complex radiotherapy treatment plans by simulating treatments and generating real dose measurements in relation to a three-dimensional target volume.  Delta4PT has been used in the validation of new treatment techniques such as Varian's RapidArc.  Delta4PT has been in clinical use for IMRT and arc therapy QA since 2006 and is used today in clinics world-wide.

"At ScandiDos we are very proud to have Varian, the largest world-wide supplier of radiation therapy systems and developer of new innovative technologies such as TrueBeam™ and RapidArc®, distributing our QA systems.  We look forward to continue to offer QA solutions to Varian and its customers with our Delta4 system when implementing new modalities in the future," says Gorgen Nilsson, CEO at ScandiDos.

SOURCE ScandiDos

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Low-dose boost of radiotherapy keeps young breast cancer patients recurrence-free